Emergency department telehealth program reduces wait time by 6 minutes

Patients in rural hospitals using telehealth services were seen by a provider six minutes faster than patients without telehealth, according to a study conducted by the University of Iowa.

In this study, researchers evaluated the impact an emergency department (ED)-based telemedicine program could have on ED wait times in rural hospitals. Factors of door-to-provider time, ED length-of-stay and time-to-transfer were included.

Of the 127,928 eligible ED encounters collected from patients from 14 rural hospitals, with 2,857 using the telehealth program who were matched with a control group counterpart. Results showed the door-to-provider time was six minutes faster in patients using the telehealth program. In 47.1 percent of telehealth encounters, the first person to see the patient was a telehealth provider who arrived 14.7 minutes before local providers. Additionally, ED length-of-stay was longer for telehealth patients, but the ED length-of-stay for transfer patients was 22.1 minutes shorter.

“Telemedicine decreases ED door-to-provider time, most commonly because the telemedicine provider was the first provider seeing a patient,” concluded first author Nicholas M. Mohr, MD, MS, and colleagues. “Among transferred patients, ED LOS at the first hospital was shorter in patients who had telemedicine consulted. Future work will focus on the clinical impact of more timely rural ED care.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.